Results 231 to 240 of about 6,018,350 (361)
Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source
Correction: Mixed cryoglobulinaemia vasculitis secondary to marginal zone lymphoma in a patient with end‑stage renal failure on haemodialysis. [PDF]
CEN Case RepCoorey CP, Aarabi A, Kumar K.
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
A Finite Sample Correction for the Variance of Linear Two-Step GMM Estimators
, 2000 F. Windmeijer
semanticscholar +1 more source
Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue‐specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations.
Alejandra González‐Duarte +13 more
wiley +1 more source
Author Correction: Combination of PARP and KRAS<sup>G12D</sup> inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. [PDF]
Nat CommunXu X +9 more
europepmc +1 more source